Mike Quigley

R&D leader at Sanofi. Presented at Session I on the productivity paradox and decision systems for scalable discovery.

Key Arguments

• The productivity paradox won’t be solved by more science — it requires treating discovery as a continuous decision ecosystem
• Three pillars: where to invest, how to source, when to advance
• Sanofi’s constellation view maps biologies across therapeutic areas (not within them), with immunoscience as the core node
• Built an agentic AI workflow that proposes real-time decisions across Sanofi’s internal pipeline, Ventures, Capital, and BD/M&A

On AI

• Today’s table stakes: regulatory submissions, trial-site optimization, enrollment, supply chain, AI-enabled DMTA
• The unsolved part: end-to-end connectivity from target ID through clinical pharmacology with iterative reverse translation
• Worry: AI tools eroding critical thinking in early scientists who outsource the next-experiment question to a model

“Therapeutic discovery is not a series of successive experiments. It is a decision ecosystem.”